FDA accepts Milestone's CRL response for CARDAMYST; new PDUFA Dec 13, 2025

Milestone Pharmaceuticals Inc.

FDA accepted Milestone's response to CRL for CARDAMYST (etripamil) nasal spray for PSVT; new PDUFA target date Dec 13, 2025.
$75M Royalty Purchase Agreement with RTW extended; approval deadline moved from Sept 30, 2025 to Dec 31, 2025.
CRL response submitted June 13, 2025 after FDA Type A meeting; included additional nitrosamine studies and facility transfer.
FDA raised no concerns regarding clinical section of NDA.
RTW proceeds expected to aid CARDAMYST commercial launch if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.